CEL-SCI Reports 73.4% Five-Year Survival With Multikine in Biomarker-Selected Head and Neck Cancer Patients

• CEL-SCI presented new analyses from its completed Phase 3 Multikine study at the World Congress on Otology, Rhinology and Laryngology in Rome.
• Multikine improved survival versus standard care alone in selected head and neck cancer patients receiving treatment before surgery.
• Patients without lymph node involvement and with low or no tumor PD-L1 expression showed the strongest survival benefit.
• Pre-surgical treatment increased tumor responses without increasing severe adverse events; no deaths were attributed to Multikine.
• The findings underpin an upcoming 212-patient U.S. registration study designed to prospectively confirm the results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260800BIZWIRE_USPR_____20261026_BW718879) on October 26, 2026, and is solely responsible for the information contained therein.